国际肿瘤学杂志

国际肿瘤学杂志 ›› 2015, Vol. 42 ›› Issue (3): 235-237.doi: 10.3760/cma.j.issn.1673422X.2015.03.020

• 综述 • 上一篇    下一篇

CD44与抗白血病效应的研究进展

王愿,高晓晗,郝洪岭   

  1. 050000 石家庄，河北医科大学研究生学院；河北省人民医院血液科
  • 出版日期:2015-03-08 发布日期:2015-01-29
  • 通讯作者: 郝洪岭，Email： h0707@163.com E-mail:h0707@163.com

The research progress of CD44 and antileukemia effect

Wang Yuan, Gao Xiaohan, Hao Hongling   

  1. Graduate School of Hebei Medical University; Department of Hematology, Heibei General Hospital, Shijiazhuang 050000, China
  • Online:2015-03-08 Published:2015-01-29
  • Contact: Hao Hongling E-mail:h0707@163.com

PDF

1472

被引次数

4

摘要： 白血病是一种造血干细胞的恶性克隆性疾病。其发病机制与白血病细胞增殖失控、分化障碍、凋亡受阻等有关。研究证实白血病细胞表达CD44，它通过参与细胞黏附、增殖、迁移、浸润等行为促进白血病的发生发展。体外试验表明，以CD44为靶点的治疗能有效杀伤白血病细胞，并降低对正常组织的细胞毒性。因此，针对CD44抗癌药物的设计有望用于白血病的临床治疗。

关键词: 白血病, CD44

Abstract: Leukemia is a kind of cloning disease from malignant hematopoietic stem cells. Its pathogenesis may have relationship with proliferation out of control, dysdiffreentiation and inhibition of apoptosis about leukemia cells. The study confirms that  CD44 is expressed in leukemia cells, promoting the occurrence and development of leukemia through participation in cell adhension, proliferation, migration and invasion behavior. In vitro experiment shows that CD44 targeted therapies can effectively kill leukemia cells, and reduce the toxicity to normal tissue cells. Therefore, aiming at the design of the anticancer drugs targeted for CD44 is expected to be used in clinical treatment of leukemia.

Key words: Leukemia, CD44